Stem cells

Induced Pluripotent Stem Cells Show Success in Treating Hemophilia A in Mice

Retrieved on: 
Thursday, March 12, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Developmental biology, Induced pluripotent stem cell, Embryonic stem cell, Induced stem cells

These cells can then be genetically modified to produce high levels of a clotting protein that was used to successfully treat hemophilia A in mice.

Key Points: 
  • These cells can then be genetically modified to produce high levels of a clotting protein that was used to successfully treat hemophilia A in mice.
  • In the study published in SCTM, the researchers explored endothelial cells (ECs) derived from hemophilia A patients' induced pluripotent stem cells (HA-iPSC-ECs) as a way to deliver FVIII.
  • To conduct their study, they collected cells from patients with hemophilia A, induced them to become induced pluripotent stem cells and then ECs and genetically modified the cells to express high levels of FVIII.
  • About STEM CELLS Translational Medicine: STEM CELLS Translational Medicine (SCTM), co-published by AlphaMed Press and Wiley, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology.

San Diego Academy of Regenerative Therapies (SDARTs) Announces 4th Annual Conference Featuring World’s Leading Experts in Microfat, Nanofat, PRP and Energy Devices

Retrieved on: 
Thursday, March 12, 2020
Science, Stem cells, Biotechnology, Research, Surgery, Health, Continuing, Education, Medicine, Cosmetic surgery, Aesthetic medicine, Practice of medicine, Plastic surgery, Surgery, Regenerative medicine, Minimally invasive procedure

Last years conference was a tremendous success, reports Marcille Pilkington, CEO of SDARTs.

Key Points: 
  • Last years conference was a tremendous success, reports Marcille Pilkington, CEO of SDARTs.
  • We had nearly 150 attendees and faculty from 19 countries, representing experts and practitioners of leading-edge regenerative therapies.
  • This year, well build on that success with a focus on the latest applications in this fast-growing new field.
  • SDARTs offers training courses in surgical and minimally invasive office-based procedures using regenerative therapies in Aesthetic Medicine, Plastic and Reconstructive Surgery, and Regenerative Medicine.

Aldevron Names Vijay Surapaneni as Vice President Biomanufacturing Operations

Retrieved on: 
Thursday, March 12, 2020
Infectious diseases, FDA, Genetics, Clinical trials, Cardiology, Stem cells, Biotechnology, Pharmaceutical, Health, Oncology, Articles, Life sciences, Industries, Biopharmaceuticals, Biomanufacturing, Food industry, Pharmaceutical industry, Biotechnology, Manufacturing

Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins, mRNA and antibodies for the biotech industry, has hired Vijay Surapaneni as its Vice President of Biomanufacturing Operations.

Key Points: 
  • Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins, mRNA and antibodies for the biotech industry, has hired Vijay Surapaneni as its Vice President of Biomanufacturing Operations.
  • View the full release here: https://www.businesswire.com/news/home/20200312005120/en/
    Aldevron Names Vijay Surapaneni as Vice President Biomanufacturing Operations (Photo: Business Wire).
  • Surapaneni brings over 30 years of global leadership experience in pharmaceutical and device technology, operations, and engineering.
  • I am excited about the opportunity to join Aldevron and drive the execution of the growth strategies and talent development, commented Surapaneni.

Pluristem and Charité University of Medicine Berlin Join Forces Targeting Potential Treatment for Respiratory and Inflammatory Intratissue Complications Caused by COVID-19

Retrieved on: 
Thursday, March 12, 2020
Medical specialties, Branches of biology, Medicine, Intensive care medicine, Stem cells, Biotechnology, Pluristem Therapeutics, Technion – Israel Institute of Technology, Acute respiratory distress syndrome, Cell therapy, Respiratory distress syndrome, Sepsis

Clinical data using PLX cells demonstrated the strong immunomodulatory potency of PLX cells in patients post major surgery.

Key Points: 
  • Clinical data using PLX cells demonstrated the strong immunomodulatory potency of PLX cells in patients post major surgery.
  • The primary target is to prevent the deterioration of patients towards Acute Respiratory Distress Syndrome (ARDS) and sepsis.
  • The BIH Center for Regenerative Therapies (BCRT) is a cooperative translational research institution of the Charit University Hospital in Berlin and the Berlin Institute of Health (BIH).
  • Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates.

BIOCARDIA ANNOUNCES TIMING FOR PRESPECIFIED DATA SAFETY MONITORING BOARD REPORT ON PIVOTAL CARDIAMP HEART FAILURE TRIAL

Retrieved on: 
Thursday, March 12, 2020
Branches of biology, Biology, Life sciences, Stem cells, Clinical research, Design of experiments, Biotechnology, Medical statistics, Clinical trial, Stem-cell therapy, Cell therapy, Blinded experiment

The report will be based on a review of all available safety data from all patients randomized in the trial.

Key Points: 
  • The report will be based on a review of all available safety data from all patients randomized in the trial.
  • A replay of the webcast will be available for a limited time on the BioCardia website following the presentation.
  • The ongoing multi-center, double-blinded, randomized (3:2), sham-controlled pivotal CardiAMP Heart Failure Trial is expected to enroll 260 patients at up to 40 centers nationwide.
  • The CardiAMP Heart Failure Trial is the first multi-center clinical trial of a stem cell therapy to prospectively screen for stem cell therapeutic potency in order to improve patient outcomes.

Medical Devices Market in Japan 2020-2024 | Evolving Opportunities with Baxter International Inc. and Becton, Dickinson and Co. | Technavio

Retrieved on: 
Thursday, March 12, 2020
Medical devices, Women, Hospitals, Dental, Cardiology, Stem cells, Pharmaceutical, Consumer, Health, Oncology, Medical terminology, Medical device, Disease, Medicine, Kidney disease

In addition, the advent of DevOps is anticipated to boost the growth of the medical devices market in Japan.

Key Points: 
  • In addition, the advent of DevOps is anticipated to boost the growth of the medical devices market in Japan.
  • The Japanese government has taken various measures to strengthen its healthcare system by allocating research funds for medical R&D.
  • These factors are encouraging vendors to introduce innovative and effective medical devices, which is driving the growth of the medical devices market in Japan.
  • The company offers medical devices to treat chronic and acute medical conditions, immune disorders, kidney disease, and hemophilia.

Insights Into the $8.8 Billion Cell Therapy Industry, 2020-2027 - Rising Adoption of Regenerative Medicine, Introduction of Novel Platforms & Technologies

Retrieved on: 
Wednesday, March 11, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Emerging technologies, Regenerative biomedicine, Regenerative medicine, Therapy, Cell therapy, Stem-cell therapy

The global cell therapy market size is expected to reach USD 8.8 billion by 2027 at a CAGR of 5.4%, over the forecast period.

Key Points: 
  • The global cell therapy market size is expected to reach USD 8.8 billion by 2027 at a CAGR of 5.4%, over the forecast period.
  • Currently, there are a limited number of FDA-approved commercial stem and non-stem cell therapies in the market.
  • Key developers are making substantial investments in the adoption of advanced technologies to address the aforementioned challenges.
  • For instance, MaxCyte has more than 40 high-value cellular therapy partnership programs within immune-oncology, regenerative medicine, and gene editing, including fifteen clinical-stage programs.

Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2020

Retrieved on: 
Wednesday, March 11, 2020
Stem cells, Branches of biology, Biology, Life sciences, Cord blood bank, Cord blood, Umbilical cord, Hematopoietic stem cell, Cordlife, Cells4Life

Revenues increased by 31.7% YoY to RMB334.7 million ($48.1 million) in the third quarter of fiscal 2020.

Key Points: 
  • Revenues increased by 31.7% YoY to RMB334.7 million ($48.1 million) in the third quarter of fiscal 2020.
  • For the first nine months of fiscal year 2020, total revenues increased by 25.4% YoY to RMB921.6 million ($132.4 million).
  • Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses.
  • Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.

Transgene: Major R&D Milestones Achieved in 2019 and Strong Clinical Activity In 2020

Retrieved on: 
Wednesday, March 11, 2020
Other Health, Research, Pharmaceutical, Oncology, Infectious diseases, Genetics, Clinical trials, Science, Biotechnology, Stem cells, Other Science, Health, Health, Clinical research, Oncolytic virus, Medical research, Clinical trial

Philippe Archinard, Chairman and Chief Executive Officer of Transgene, commented:

Key Points: 
  • Philippe Archinard, Chairman and Chief Executive Officer of Transgene, commented:
    We achieved multiple important advances with our novel myvac and Invir.IO platforms during the course of 2019.
  • This platform has also generated a number of exciting new oncolytic candidates, including BT-001, which is being co-developed with BioInvent.
  • This program will generate a significant body of data evaluating the activity of TG4050 from these initial clinical trials.
  • A candidate is expected to be selected with the aim of submitting a clinical trial application in 2H 2020 ahead of starting a clinical trial in 2021.